July 12, 2026
4 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
Subcutaneous, intravenous outcomes with lecanemab comparable in Alzheimer’s disease
Outcomes following subcutaneous and intravenous treatment with lecanemab for Alzheimer’s disease were comparable, according to a group of abstracts presented at the Alzheimer’s Association International Conference.Intravenous lecanemab (Leqembi, Eisai) has yielded substantial reductions in amyloids and significantly slower clinical decline, Michael Irizarry, MD, MPH, senior vice
1,251 words~6 min read
